Vanguard Group Inc. Has $53.51 Million Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Vanguard Group Inc. increased its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 6.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,693,343 shares of the company's stock after buying an additional 98,685 shares during the quarter. Vanguard Group Inc. owned about 3.63% of Mirum Pharmaceuticals worth $53,510,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in MIRM. China Universal Asset Management Co. Ltd. lifted its position in Mirum Pharmaceuticals by 98.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company's stock worth $31,000 after purchasing an additional 488 shares during the period. Royal Bank of Canada lifted its position in Mirum Pharmaceuticals by 40.1% in the second quarter. Royal Bank of Canada now owns 1,851 shares of the company's stock worth $48,000 after purchasing an additional 530 shares during the period. Tower Research Capital LLC TRC lifted its position in Mirum Pharmaceuticals by 186.6% in the second quarter. Tower Research Capital LLC TRC now owns 1,846 shares of the company's stock worth $48,000 after purchasing an additional 1,202 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in Mirum Pharmaceuticals in the first quarter worth approximately $49,000. Finally, Ameritas Investment Partners Inc. lifted its position in shares of Mirum Pharmaceuticals by 85.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,208 shares of the company's stock valued at $57,000 after acquiring an additional 1,016 shares during the last quarter.

Mirum Pharmaceuticals Stock Up 1.1 %

NASDAQ:MIRM traded up $0.28 during trading hours on Tuesday, hitting $26.20. 402,532 shares of the stock traded hands, compared to its average volume of 590,521. The firm has a 50 day moving average price of $27.29 and a 200 day moving average price of $28.84. The company has a current ratio of 4.45, a quick ratio of 4.19 and a debt-to-equity ratio of 1.23. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $22.34 and a fifty-two week high of $35.56. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -6.53 and a beta of 1.14.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 66.24% and a negative net margin of 86.33%. The company had revenue of $69.55 million during the quarter, compared to analyst estimates of $66.73 million. Equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.12 earnings per share for the current year.

Wall Street Analyst Weigh In

MIRM has been the subject of a number of recent research reports. Raymond James cut their price objective on Mirum Pharmaceuticals from $78.00 to $64.00 and set a "strong-buy" rating for the company in a research report on Tuesday, December 19th. Cantor Fitzgerald reiterated an "overweight" rating and set a $35.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, February 29th. SVB Leerink cut their price objective on Mirum Pharmaceuticals from $44.00 to $43.00 and set an "outperform" rating for the company in a research report on Monday, March 18th. HC Wainwright reiterated a "buy" rating and set a $58.00 price objective on shares of Mirum Pharmaceuticals in a research report on Tuesday, April 2nd. Finally, JMP Securities boosted their target price on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an "outperform" rating in a research note on Thursday, March 14th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $52.11.

Insider Transactions at Mirum Pharmaceuticals

In related news, CFO Eric Bjerkholt purchased 2,000 shares of the company's stock in a transaction dated Wednesday, March 27th. The shares were acquired at an average cost of $24.80 per share, with a total value of $49,600.00. Following the completion of the purchase, the chief financial officer now owns 14,000 shares of the company's stock, valued at approximately $347,200. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, COO Peter Radovich sold 4,303 shares of the company's stock in a transaction on Monday, March 25th. The shares were sold at an average price of $25.80, for a total value of $111,017.40. Following the transaction, the chief operating officer now directly owns 29,013 shares of the company's stock, valued at $748,535.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Eric Bjerkholt bought 2,000 shares of the stock in a transaction on Wednesday, March 27th. The shares were acquired at an average cost of $24.80 per share, for a total transaction of $49,600.00. Following the completion of the transaction, the chief financial officer now directly owns 14,000 shares of the company's stock, valued at $347,200. The disclosure for this purchase can be found here. 24.06% of the stock is currently owned by company insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.